Relvar Ellipta meets primary in Salford real-world asthma outcomes study

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Innoviva Inc. (NASDAQ:INVA) said Relvar Ellipta fluticasone furoate/vilanterol (GW685698/GW64244) met the primary endpoint in the open-label, U.K. Phase III Salford Lung Study in 4,233 patients with asthma. Specifically, 71% of patients who switched from their usual treatment regimen to Relvar Ellipta had improved control of their asthma at week 24 vs. 56% of patients who continued with their usual care (p<0.001). Improved asthma control was defined as an Asthma Control Test (ACT) total score of ≥20 points or an improvement from baseline of ≥3 points.

The trial enrolled patients who were on maintenance therapy with an inhaled corticosteroid with or without a long-acting adrenergic receptor beta 2 agonist (LABA). Physicians were allowed to modify or switch treatment at any point, except to switch from usual care to Relvar Ellipta. Patients received either 100/25 or 200/25 μg doses of fluticasone furoate/vilanterol...